|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Angina pectoris |
|
Hypertension, essential |
|
Myocardial infarction |
| |
|
|
SIDE EFFECTS:
|
|
alopecia |
|
AV block |
|
bronchospasm |
|
depression |
|
diabetes mellitus |
|
diarrhea |
|
dizziness |
|
drowsiness |
|
dyspnea |
|
elevated hepatic enzymes |
|
fatigue |
|
hallucinations |
|
headache |
|
heart failure |
|
hyperbilirubinemia |
|
hyperglycemia |
|
hypertriglyceridemia |
|
hypoglycemia |
|
hypotension |
|
impotence |
|
lupus-like symptoms |
|
nausea/vomiting |
|
nightmares |
|
orthostatic hypotension |
|
psoriaform rash |
|
psoriasis |
|
psychosis |
|
purpura |
|
rash (unspecified) |
|
sinus bradycardia |
|
skin hypopigmentation |
|
syncope |
|
teratogenesis |
|
thrombocytopenia |
|
vertigo |
|
visual impairment |
|
wheezing |
|
xerophthalmia |
|
xerostomia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
asthma |
|
breast-feeding |
|
bronchitis |
|
chronic obstructive pulmonary disease (COPD) |
|
depression |
|
diabetes mellitus |
|
dialysis |
|
driving or operating machinery |
|
elderly |
|
emphysema |
|
heart failure |
|
hyperthyroidism |
|
hypotension |
|
myasthenia gravis |
|
peripheral vascular disease |
|
pheochromocytoma |
|
pregnancy |
|
psoriasis |
|
pulmonary disease |
|
Raynaud's disease |
|
renal disease |
|
renal failure |
|
renal impairment |
|
surgery |
|
thyroid disease |
|
thyrotoxicosis |
|
vasospastic angina |
|
|
ADULT DOSE:
|
|
Antianginal-Oral, initially 50 mg once a day, the dosage being increased gradually to 100 mg a day after one week if necessary and tolerated .
Some patients may require up to 200 mg a day.
Antihypertensive-Oral, initially 25 to 50 mg once a day, the dosage being increased to 50 to 100 mg a day after two weeks if necessary and tolerated.
Myocardial infarction-In patients who tolerate the full intravenous dose: Oral, initially 50 mg ten minutes after the last intravenous dose, followed by another 50 mg twelve hours later .
A dose of 100 mg once a day or 50 mg two times a day may then be given for six to nine days or until discharge from the hospital .
Note: Geriatric patients may have increased or decreased sensitivity to the effects of the usual adult dose.
For patients with severe renal function impairment, the following maximum doses are recommended:
Creatinine clearance Maximum
(mL/min/1.73m) dose
15-35 50 mg per day
<15 50 mg every second day |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Dosage has not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|